_id
69105bc5ccc777a4e85d5818
Ticker
DMKPQ
Name
DMK Pharmaceuticals Corporation
Exchange
PINK
Address
11682 El Camino Real, San Diego, CA, United States, 92130
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD
Website
https://www.dmkpharmaceuticals.com
Description
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 28, 2024.
Last Close
0.0001
Volume
2
Current Price
0.0001
Change
0
Last Updated
2025-11-09T09:15:48.403Z
Image
-
Ipo Date
-
Market Cap
1009
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2023-09-30
Revenue
9062
Cost Of Revenue
340620
Gross Profit
-331558
Operating Expenses
2933547
Operating Income
-3265105
Interest Expense
29465
Pretax Income
-1736248
Net Income
-1388046
Eps
-0.19644922712953175
Dividends Per Share
-
Shares Outstanding
7065673
Income Tax Expense
-348204
EBITDA
-1704654
Total Other Income Expense Net
-
Cash
6663921
Short Term Investments
-
Receivables
0
Inventories
662962
Total Current Assets
7872061
Property Plant Equipment
1075676
Total Assets
8957411
Payables
9973413
Short Term Debt
63209
Long Term Debt
-
Total Liabilities
14252050
Equity
-5285149
Depreciation
67193
Change In Working Capital
-1315159
Cash From Operations
-3737240
Capital Expenditures
0
Cash From Investing
1767391
Cash From Financing
7963426
Net Change In Cash
5993577
PE
-
PB
-0.00013368919211170774
ROE
26.263138465916473
ROA
-15.496062422501321
FCF
-3737240
Fcf Percent
-412.40785698521296
Piotroski FScore
0
Health Score
30
Deep Value Investing Score
2.5
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
6.8
Garp Investing Score
4.5
Growth Investing Score
4.5
Momentum Investing Score
4
Net Net Investing Score
2
Quality Investing Score
3
Value Investing Score
3
Quarters > 0 > quarter
2023-09-30
Quarters > 0 > income Statement > revenue
9062
Quarters > 0 > income Statement > cost Of Revenue
340620
Quarters > 0 > income Statement > gross Profit
-331558
Quarters > 0 > income Statement > operating Expenses
2933547
Quarters > 0 > income Statement > operating Income
-3265105
Quarters > 0 > income Statement > interest Expense
29465
Quarters > 0 > income Statement > pretax Income
-1736248
Quarters > 0 > income Statement > net Income
-1388046
Quarters > 0 > income Statement > eps
-0.19644922712953175
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
7065673
Quarters > 0 > income Statement > income Tax Expense
-348204
Quarters > 0 > income Statement > EBITDA
-1704654
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > balance Sheet > cash
6663921
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
0
Quarters > 0 > balance Sheet > inventories
662962
Quarters > 0 > balance Sheet > total Current Assets
7872061
Quarters > 0 > balance Sheet > property Plant Equipment
1075676
Quarters > 0 > balance Sheet > total Assets
8957411
Quarters > 0 > balance Sheet > payables
9973413
Quarters > 0 > balance Sheet > short Term Debt
63209
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
14252050
Quarters > 0 > balance Sheet > equity
-5285149
Quarters > 0 > cash Flow > net Income
-1736248
Quarters > 0 > cash Flow > depreciation
67193
Quarters > 0 > cash Flow > change In Working Capital
-1315159
Quarters > 0 > cash Flow > cash From Operations
-3737240
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
1767391
Quarters > 0 > cash Flow > cash From Financing
7963426
Quarters > 0 > cash Flow > net Change In Cash
5993577
Quarters > 0 > ratios > PE
-0.19644922712953175
Quarters > 0 > ratios > PB
-0.00013368919211170774
Quarters > 0 > ratios > ROE
26.263138465916473
Quarters > 0 > ratios > ROA
-15.496062422501321
Quarters > 0 > ratios > FCF
-3737240
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-412.40785698521296
Quarters > 0 > health Score
30
Quarters > 1 > quarter
2023-06-30
Quarters > 1 > income Statement > revenue
6945
Quarters > 1 > income Statement > cost Of Revenue
441940
Quarters > 1 > income Statement > gross Profit
-434995
Quarters > 1 > income Statement > operating Expenses
4329494
Quarters > 1 > income Statement > operating Income
-4764490
Quarters > 1 > income Statement > interest Expense
46312
Quarters > 1 > income Statement > pretax Income
-7003391
Quarters > 1 > income Statement > net Income
-8574122
Quarters > 1 > income Statement > eps
-3.337013310500506
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
2569400
Quarters > 1 > income Statement > income Tax Expense
1570735
Quarters > 1 > income Statement > EBITDA
-6876531
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > balance Sheet > cash
670344
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
18971
Quarters > 1 > balance Sheet > inventories
664358
Quarters > 1 > balance Sheet > total Current Assets
3450698
Quarters > 1 > balance Sheet > property Plant Equipment
1288778
Quarters > 1 > balance Sheet > total Assets
4749150
Quarters > 1 > balance Sheet > payables
11365931
Quarters > 1 > balance Sheet > short Term Debt
157246
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
16244475
Quarters > 1 > balance Sheet > equity
-11495326
Quarters > 1 > cash Flow > net Income
-7003391
Quarters > 1 > cash Flow > depreciation
80546
Quarters > 1 > cash Flow > change In Working Capital
1670588
Quarters > 1 > cash Flow > cash From Operations
-2568534
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
138291
Quarters > 1 > cash Flow > cash From Financing
750
Quarters > 1 > cash Flow > net Change In Cash
-2459578
Quarters > 1 > ratios > PE
-3.337013310500506
Quarters > 1 > ratios > PB
-0.00002235169320121935
Quarters > 1 > ratios > ROE
74.58789772469262
Quarters > 1 > ratios > ROA
-180.54013876167315
Quarters > 1 > ratios > FCF
-2568534
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-369.83930885529156
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2023-03-31
Quarters > 2 > income Statement > revenue
1453000
Quarters > 2 > income Statement > cost Of Revenue
1890735
Quarters > 2 > income Statement > gross Profit
-437735
Quarters > 2 > income Statement > operating Expenses
5989946
Quarters > 2 > income Statement > operating Income
-6427680
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-9014608
Quarters > 2 > income Statement > net Income
-8942907
Quarters > 2 > income Statement > eps
-4.093759183931313
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
2184522
Quarters > 2 > income Statement > income Tax Expense
-71700
Quarters > 2 > income Statement > EBITDA
-6318211
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > balance Sheet > cash
3129922
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
21173
Quarters > 2 > balance Sheet > inventories
664358
Quarters > 2 > balance Sheet > total Current Assets
7547030
Quarters > 2 > balance Sheet > property Plant Equipment
1476891
Quarters > 2 > balance Sheet > total Assets
9076095
Quarters > 2 > balance Sheet > payables
9780979
Quarters > 2 > balance Sheet > short Term Debt
250361
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
18600473
Quarters > 2 > balance Sheet > equity
-9524378
Quarters > 2 > cash Flow > net Income
-9014608
Quarters > 2 > cash Flow > depreciation
102669
Quarters > 2 > cash Flow > change In Working Capital
4952364
Quarters > 2 > cash Flow > cash From Operations
-1547538
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
841778
Quarters > 2 > cash Flow > cash From Financing
2724250
Quarters > 2 > cash Flow > net Change In Cash
2018490
Quarters > 2 > ratios > PE
-4.093759183931313
Quarters > 2 > ratios > PB
-0.000022936111943478096
Quarters > 2 > ratios > ROE
93.89491891229012
Quarters > 2 > ratios > ROA
-98.53254070170046
Quarters > 2 > ratios > FCF
-1547538
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-1.06506400550585
Quarters > 2 > health Score
31
Quarters > 3 > quarter
2022-12-31
Quarters > 3 > income Statement > revenue
2150682
Quarters > 3 > income Statement > cost Of Revenue
2848842
Quarters > 3 > income Statement > gross Profit
-698160
Quarters > 3 > income Statement > operating Expenses
3643580
Quarters > 3 > income Statement > operating Income
-4341740
Quarters > 3 > income Statement > interest Expense
-379392
Quarters > 3 > income Statement > pretax Income
-3400989
Quarters > 3 > income Statement > net Income
-3327536
Quarters > 3 > income Statement > eps
-1.553023450750437
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
2142618
Quarters > 3 > income Statement > income Tax Expense
2000
Quarters > 3 > income Statement > EBITDA
-3033938
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > balance Sheet > cash
1111432
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
1085009
Quarters > 3 > balance Sheet > inventories
1238778
Quarters > 3 > balance Sheet > total Current Assets
9272150
Quarters > 3 > balance Sheet > property Plant Equipment
1606516
Quarters > 3 > balance Sheet > total Assets
10930840
Quarters > 3 > balance Sheet > payables
7937493
Quarters > 3 > balance Sheet > short Term Debt
342562
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
11581605
Quarters > 3 > balance Sheet > equity
-650765
Quarters > 3 > cash Flow > net Income
-3402989
Quarters > 3 > cash Flow > depreciation
367053
Quarters > 3 > cash Flow > change In Working Capital
861986
Quarters > 3 > cash Flow > cash From Operations
-1522043
Quarters > 3 > cash Flow > capital Expenditures
91494
Quarters > 3 > cash Flow > cash From Investing
155302
Quarters > 3 > cash Flow > cash From Financing
0
Quarters > 3 > cash Flow > net Change In Cash
-1338584
Quarters > 3 > ratios > PE
-1.553023450750437
Quarters > 3 > ratios > PB
-0.0003292460411976674
Quarters > 3 > ratios > ROE
511.3268230467219
Quarters > 3 > ratios > ROA
-30.44172268553926
Quarters > 3 > ratios > FCF
-1613537
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-0.7502443410973821
Quarters > 3 > health Score
31
Valuation > metrics > PE
-0.19644922712953175
Valuation > metrics > PB
-0.00013368919211170774
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
26.263138465916473
Profitability > metrics > ROA
-17.63256153629907
Profitability > metrics > Net Margin
-153.17214742882365
Profitability > final Score
40
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-110.81299847276429
Risk > final Score
-413
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.7843337130759732
Liquidity > metrics > Quick Ratio
0.7182794171186282
Liquidity > final Score
46
Liquidity > verdict
Weak
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
40
Prev Profitabilities > 1
40
Prev Profitabilities > 2
40
Prev Risks > 0
-382
Prev Risks > 1
20
Prev Risks > 2
-16
Prev Liquidities > 0
22
Prev Liquidities > 1
44
Prev Liquidities > 2
77
Updated At
2026-01-20T21:43:05.077Z
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 28, 2024.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ADMK Pharmaceuticals reports asset sale and board reshuffle Investing.com
Read more →(Last Updated 2023-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 0.00% of the total shares of DMK Pharmaceuticals Corporation
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2023-09-30)
(Last Updated 2023-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
(Last Updated 2023-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2023-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.